Seqirus first-to-market with US 2019/20 flu vaccines

Seqirus, a global leader in influenza prevention and part of Australia’s CSL Limited (ASX: CSL), announced today it is first-to-market with shipping its portfolio of seasonal influenza vaccines to customers in the USA for the 2019/20 influenza season.

Seqirus expects to distribute over 50 million doses to the US market this year, with the majority of doses coming from its adjuvanted and cell-based technology platforms.

The company will provide Fluad, the first-and-only adjuvanted seasonal influenza vaccine developed for people aged 65 and older, and Flucelvax Quadrivalent, the most widely available cell-based influenza vaccine in the country, available for those aged four and older.5